My Top 3 Stocks to Buy in Early 2026
By Christopher Patterson, Head of Corporate, RS Global Group
As investors enter a new year, portfolio diversification remains a prudent objective, particularly amid evolving economic and market conditions. Expanding exposure across sectors such as technology, consumer services, and healthcare can help enhance returns during periods of growth while providing resilience during market downturns. With this objective in mind, several companies stand out as attractive opportunities in early 2026, combining established earnings power with selective exposure to long-term growth themes.
Amazon
Amazon offers investors a diversified and relatively low-risk way to participate in the continued expansion of artificial intelligence. The company’s long-standing earnings strength is anchored in its dominant e-commerce platform and its cloud computing division, Amazon Web Services (AWS), both of which have generated substantial and consistent cash flow over time. Amazon is also leveraging AI internally to improve operational efficiency, while AWS provides a broad portfolio of AI tools and services to customers. This has helped drive AWS to an annual revenue run rate exceeding $132 billion, reinforcing Amazon’s position as a core long-term holding.
Chewy
Chewy has established itself as a leading e-commerce platform for pet products and services, offering a wide range of consumables, accessories, and healthcare solutions. The company has expanded into veterinary services through the launch of its own clinics, broadening its addressable market and creating additional touchpoints with customers. Chewy has achieved profitability while maintaining solid growth, supported by a highly recurring revenue model. Its Autoship subscription service now accounts for approximately 84% of total sales, providing strong visibility into future revenue. With shares trading at a lower forward earnings multiple than in prior years, Chewy presents an appealing entry point for long-term investors.
Moderna
Moderna represents a potential recovery opportunity within the healthcare sector. Following a period of exceptional performance driven by COVID-19 vaccine sales, the company has faced declining revenue and earnings as demand normalized. While sales of its coronavirus and respiratory syncytial virus vaccines have underperformed expectations, Moderna’s longer-term outlook is supported by a robust development pipeline. The company plans to expand its seasonal vaccine portfolio from three products today to six by 2028 and is implementing cost-reduction initiatives with the goal of reaching cash breakeven by that time. Although the stock carries higher risk, it may appeal to growth-oriented investors seeking exposure to a potential turnaround in biotechnology.
Together, these three stocks offer a blend of stability, recurring revenue, and recovery-driven upside, making them well suited for investors looking to build a diversified portfolio in early 2026.
Disclosure: The author does not hold any position in the securities discussed.
Recent Comments